Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens.

Antimicrobial Agents and Chemotherapy
Christine A PybusDavid E Greenberg

Abstract

Cefiderocol is a siderophore cephalosporin with potent antibacterial activity against a broad range of Gram-negative pathogens, including multidrug-resistant strains. Siderophore antibiotics bind ferric iron and utilize iron transporters to cross the cell membrane. In the biofilm setting, where antibiotic resistance is high but iron scavenging is important, cefiderocol may have advantageous antimicrobial properties. In this study, we compared the antimicrobial activity of cefiderocol to that of seven commonly used antibiotics in well-characterized multidrug-resistant pathogens and then determined their efficacy in the biofilm setting. MIC90 values for cefiderocol were consistently lower than those of other antibiotics (ceftolozane-tazobactam, ceftazidime-avibactam, ceftazidime, piperacillin-tazobactam, imipenem, and tobramycin) in all strains tested. Cefiderocol treatment displayed a reduction in the levels of Pseudomonas aeruginosa biofilm (93%, P < 0.0001) superior to that seen with the other antibiotics (49% to 82%). Cefiderocol was generally as effective as or superior to the other antibiotics, depending on the pathogen-antibiotic combination, in reducing biofilm in other pathogens. There was a trend toward greater biofilm ...Continue Reading

References

May 21, 1999·Science·J W CostertonE P Greenberg
Apr 5, 2002·Clinical Microbiology Reviews·Rodney M Donlan, J William Costerton
May 22, 2004·American Journal of Infection Control·Barbara W Trautner, Rabih O Darouiche
Jul 27, 2005·Proceedings of the National Academy of Sciences of the United States of America·Ehud BaninE Peter Greenberg
Aug 23, 2005·Infection and Immunity·Alexandra R MeyShelley M Payne
Dec 5, 2006·Nature Reviews. Microbiology·Kim Lewis
Feb 20, 2009·The ISME Journal·Freya Harrison, Angus Buckling
Jun 29, 2011·FEMS Microbiology Reviews·Dan I Andersson, Diarmaid Hughes
Jan 11, 2012·Antimicrobial Agents and Chemotherapy·David L MacLeodWilliam R Baker
Oct 5, 2012·Clinical Microbiology Reviews·Lucía Fernández, Robert E W Hancock
Oct 26, 2012·Interdisciplinary Perspectives on Infectious Diseases·Axel Dalhoff
Jun 5, 2013·Frontiers in Microbiology·María S RamirezMarcelo E Tolmasky
May 20, 2014·Upsala Journal of Medical Sciences·Martin Sundqvist
Oct 11, 2014·Future Microbiology·Stephen J McConougheyPaul Stoodley
Dec 2, 2014·Nature Reviews. Microbiology·Jessica M A BlairLaura J V Piddock
Feb 11, 2016·Therapeutic Advances in Infectious Disease·Georgios Meletis
Jan 1, 2013·Burns and Trauma·Daniel G Metcalf, Philip G Bowler
Nov 9, 2016·Trends in Molecular Medicine·Briana R WilsonYoshiaki Tsuji
Nov 16, 2016·Scientific Reports·Chuan-Sheng LinJohn D Young
Feb 1, 2017·Antimicrobial Agents and Chemotherapy·James J HowardDavid E Greenberg
Feb 7, 2017·International Journal of Antimicrobial Agents·Katy JeannotPatrick Plésiat
Jul 28, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J DobiasP Nordmann
Oct 25, 2017·Antimicrobial Agents and Chemotherapy·Akinobu ItoYoshinori Yamano
Nov 8, 2017·International Journal of Antimicrobial Agents·Islam M GhaziDavid P Nicolau
Nov 23, 2017·Frontiers in Cellular and Infection Microbiology·Aaron T Butt, Mark S Thomas
Mar 21, 2018·Antimicrobial Agents and Chemotherapy·Alexandre LuscherThilo Köhler
May 22, 2018·BioMed Research International·Sadeeq Ur RahmanJian Gao
Jun 28, 2018·The Journal of Microbiology·Donghoon Kang, Natalia V Kirienko
Aug 23, 2019·European Journal of Medicinal Chemistry·Huimin KongXiaojian Zhang
Sep 14, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kokob H NegashJames T Hodgkinson
Nov 15, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Takayuki KatsubeToshihiro Wajima
Nov 15, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrice Nordmann, Laurent Poirel
Nov 15, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yoshinori Yamano

❮ Previous
Next ❯

Citations

Apr 15, 2021·Expert Review of Clinical Pharmacology·Anselm Jorda, Markus Zeitlinger
May 26, 2021·Antimicrobial Agents and Chemotherapy·Erin K McCrearyPranita D Tamma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Related Papers

The Annals of Pharmacotherapy
Rania M El-Lababidi, John George Rizk
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Takafumi Sato, Kenji Yamawaki
© 2021 Meta ULC. All rights reserved